This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Delivered as Hybrid Event from 15-18 November 2022
Live In-Person Conference Delivered 15-18 NovemberAustria Center Vienna
Key Sessions
Shalini Andersson, PhD
Developing Oligonucleotides into Therapies: Opportunities and Challenges
AstraZeneca
Christian Heinis, Ph.D.
Development of Therapeutics Based on Cyclic Peptides
Ecole Polytechnique Federale de Lausanne
René Thürmer, PhD
CMC Regulatory Considerations for Oligonucleotides and Peptides: Similarities and Differences
BfArM Federal Inst for Drugs & Med Device
Karina Thorn, PhD
Progress in Oligonucleotide Drug Development: Building the Technologies and R&D Partnerships to Accelerate Discovery
Novo Nordisk
Ulrich Blaschke, PhD
mRNA Development and Manufacturing
BioNTech AG
Michael Skynner, Ph.D.
Bi-cyclic Peptide (Bicycle®) Mediated Delivery of RNA-targeted Therapeutics
Bicycle Therapeutics